ERBB2 and triple-negative breast carcinoma: Of the remaining 51 publications, 46 were excluded because they did not meet all the inclusion criteria: 11 were reviews, 5 were abstracts or posters, 11 were non-interventional clinical trials, 16 were clinical trials involving populations other than those being analyzed in this review (early breast cancer, HR- and/or HER2 positive, or triple-negative breast cancer), 1 was a phase II study, and 2 studies did not include ET in the therapeutic regimens investigated.